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Serum Midkine, estimated 
glomerular filtration rate 
and chronic kidney disease‑related 
events in elderly women: perth 
Longitudinal Study of Aging 
Women
Jeffrey Wang1,9*, Joshua R. Lewis2,3,4,9, elizabeth Byrnes6,9, Germaine Wong2, 
Warren D. Raymond3,4, Kun Zhu4,5, Graham R. Robertson7, Wai H. Lim4,8, Qi cao1, 
Richard L. prince4,5 & Vincent W. Lee1,2
Midkine (MDK), a heparin‑binding growth factor cytokine, is involved in the pathogenesis of kidney 
diseases by augmenting leukocyte trafficking and activation. Animal models and small case control 
studies have implicated MDK as a pathological biomarker in chronic kidney diseases (cKD), however 
this is yet to be confirmed in prospective human studies. In a prospective study of 499 elderly, 
predominantly Caucasian women aged over 70 years the association between serum MDK collected 
in 1998, and renal function change and the risk of CKD-related hospitalisations and deaths at 5 and 
14.5 years, respectively, was examined. Baseline serum MDK was not associated with 5-year change 
in estimated glomerular filtration rate using the CKD Epidemiology Collaboration creatinine and 
cystatin C equation (Standardised β = − 0.09, 95% confidence interval − 3.76–0.48, p = 0.129), 5-year 
rapid decline in renal function (odds ratio = 0.97, 95% confidence interval 0.46–2.02, p = 0.927) or the 
risk of 14.5-year CKD-related hospitalisations and deaths (hazard ratio = 1.27, 95% confidence interval 
.66–2.46, p = 0.470) before or after adjusting for major risk factors. In conclusion, in this cohort of 
elderly women with normal or mildly impaired renal function, serum MDK was not associated with 
renal function change or future cKD‑related hospitalisations and deaths, suggesting that MDK may 
not be an early biomarker for progression of cKD.
Chronic kidney disease (CKD) is a major global health concern, estimated to affect approximately 8–16% of the 
population  worldwide1. End-stage kidney disease (ESKD), the most feared outcome for patients with CKD, is 
also associated with co-morbidities such as cardiovascular disease (CVD), and premature  mortality2. The current 
standard measures such as estimated glomerular filtration rate (eGFR) and albuminuria are moderate perform-
ers at predicting disease progression to end-stage disease. Better estimates at earlier stage disease are needed 
to enable therapeutic interventions to minimise progression. While there have been a selection of biomarkers 
open
1Centre for Transplant and Renal Research, University of Sydney at Westmead Institute of Medical Research, 
Westmead  2145,  Australia.  2Centre for Kidney Research, Children’s Hospital at Westmead School of Public 
Health,  Sydney  Medical  School,  The  University  of  Sydney,  Sydney  2006,  Australia.  3School of Medical and 
Health  Sciences,  Edith Cowan University,  Joondalup  6027, Australia.  4Faculty of Health and Medical Sciences, 
The  University  of  Western  Australia,  Perth  6009,  Australia.  5Department of Endocrinology and Diabetes, Sir 
Charles Gairdner Hospital, Perth 6009, Australia. 6PathWest, QEII Medical Centre, Perth 6009, Australia. 7Lyramid 
Limited,  Sydney  2000,  Australia.  8Department  of  Renal  Medicine,  Sir  Charles  Gairdner  Hospital,  Perth  6009, 
Australia.  9These  authors  contributed  equally:  Jeffrey  Wang,  Joshua  R.  Lewis  and  Elizabeth  Byrnes. *email: 
jwan3534@uni.sydney.edu.au
2Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:14499  | https://doi.org/10.1038/s41598-020-71353-8
www.nature.com/scientificreports/
used to assess both innate kidney function and kidney  damage3, most of these biomarkers have not been found 
sufficiently predictive of kidney function decline or disease progression to be used in routine clinical practice.
Midkine (MDK) is a heparin-binding cytokine most notably known for its role in embryonic development 
and cancer through promoting cell migration, survival, proliferation and  angiogenesis4–7. In addition to its mito-
genic properties, MDK also displays immunomodulatory functions which have been demonstrated in various 
inflammatory and autoimmune  diseases8–12. Mechanism studies have shown that in the kidney, MDK promotes 
chemokine production and leukocyte trafficking post-kidney injury, and has been associated with increased renal 
inflammation, fibrosis and deterioration, indicating that MDK may play a role in mediating the pathogenesis 
of kidney  diseases13–17.
A number of observational studies of individuals with acute kidney injury (AKI) or CKD have suggested 
MDK is clinically relevant with renal disease. One cross-sectional study in a CKD cohort showed that serum 
and urine MDK levels were inversely correlated with eGFR, and also elevated in patients with CKD stage 3 or 
 above18. A few studies have reported that serum and urine MDK are predictive of AKI outcomes in post-cardiac 
surgery  patients19–21. However, there is no prospective data available about the association between MDK and 
renal function decline and CKD development. This study aimed to determine the association between serum 
MDK and longitudinal changes in renal function; and CKD-related clinical events in a large cohort of elderly 
women with long-term clinical follow-up.
Methods
All methods were carried out in accordance with relevant guidelines and regulations.
Study population. The participants for this study were originally recruited in 1998 to a 5-year prospec-
tive, randomised, controlled trial of oral calcium supplements (1.2 g of elemental calcium daily), or an identical 
placebo to prevent osteoporotic fractures, the Calcium Intake Fracture Outcome Study (CAIFOS)22. Briefly, 
women aged over 70 years were recruited from the Western Australian general population by mail using the 
electoral roll, which is a requirement of Australian citizenship. Of the 5,586 who were approached, 1,500 were 
consented and recruited for the study. All participants were ambulant with an expected survival beyond 5 years 
and were not receiving any medication (including hormone replacement therapy) known to affect bone metabo-
lism. Baseline disease burden, CVD risk and medications were comparable between these participants and the 
general population of similar age although these participants were more likely to be from higher socio-economic 
 groups22. At the conclusion of CAIFOS, participants were subsequently included in additional follow-up studies 
for a further 10 years as the Perth Longitudinal Study of Aging in Women (PLSAW) https ://www.lsaw.com.au, 
for a total follow-up period of 15 years. All participants that received placebo, or calcium treatment (calcium 
treatment code) from the CAIFOS were included for this study. Inclusion criteria for participants included all 
available exposure, confounding and outcome variables. Exclusion criteria included missing or invalid data on 
serum MDK, missing data on serum creatinine, cystatin C or both, and loss of follow-up data for clinical events 
(see Supplementary Fig. S1 and Supplementary Table S1 online).
Baseline assessment. Baseline characteristics were assessed to determine potential confounding vari-
ables, which included age, body mass index (BMI), medical history and renal function. Treatment code (placebo 
or calcium) over the 5  years of the CAIFOS trial was also included as a covariate. Baseline medical history 
(diabetes and hypertension) was available from the demographic questionnaire, with the latter being verified 
by the participants’ general practitioners where possible. These data were coded using the International Clas-
sification of Primary Care-Plus (ICPC-Plus)  method23. The coding methodology allows aggregation of different 
terms for similar pathological entities as defined by the ICD-10 coding system. Previous atherosclerotic vascular 
disease (ASVD) from 1980–1998 was determined from the Western Australian Hospital Morbidity Data Collec-
tion of primary discharge  diagnosis24. The use of cardiovascular medications including blood pressure lowering 
agents and statins was assessed. Weight was assessed using digital scales with participants wearing light clothes 
and no shoes. Height was assessed using a stadiometer and the BMI was calculated using the following equa-
tion = weight (kg)/[height (m)]2. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine and cystatin C  formula25.
Biochemistry. Venous blood samples were collected between 0830 and 1030 h after overnight fasting at 
baseline and were stored at − 80 °C until assessment. In 2005, serum creatinine was measured from baseline 
serum samples using an isotope dilution mass spectrometry (IDMS) traceable Jaffe kinetic assay for creatinine 
(Hitachi 917 auto-analyzer, Roche Diagnostics GmbH, Mannheim Germany), whereas 5-year serum creatinine 
was measured in 2012 on the Architect ci16200 analyzer (Abbott Laboratories, Abbott Park, Ill., USA)26. Serum 
cystatin C was measured using a fully automated particle-enhanced immunoturbidimetric assay with Senti-
nel Diagnostics reagents (Sentinel CH, Milan, Italy) on the Architect ci 16200 System (Abbott Laboratories, 
Abbott Park, Ill., USA) according to the manufacturer’s instructions. The correlation coefficient  (r2) between 
the machines was 0.998 with a Passing and Bablok slope of 0.966 and a Passing and Bablok intercept of 6.16 
(n = 37)26.
Midkine assay. MDK was measured in 2019 using a colourimetric enzyme-linked immunosorbent assay 
(human MDK SimpleStep ELISA kit—product ab193761: Abcam, Sydney, Australia)27 in baseline serum sam-
ples on the BioTek ELx800 Absorbance Microplate reader with BioTek Gen5 plate reading software (BioTek, 
Vermont, USA). The sensitivity (lowest detection limit) was 5  pg/mL, while the highest detection limit was 
2096 pg/mL. The intra-assay and inter-assay coefficient of variance (CV) values were 5.57% and 14.26% respec-
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tively. For statistical purposes all samples below the lowest detection limit (n = 1) were assigned a value half of 
the lowest detection limit (2.5 pg/mL), while all values above the highest detection limit (n = 8) were assigned 
a value of the highest detection limit (2096 pg/mL). A change in the Abcam MDK SimpleStep ELISA kit lot led 
to high background absorbance for the standards (p < 0.001 for difference in kits) which could not be rectified 
after suggested amendments to the protocols from the manufacturer. We therefore excluded all results from the 
second batch of kit lots (n = 17 plates).
Assessment of follow‑up chronic kidney disease‑related hospitalisations and deaths. The 
Western Australian Hospital Morbidity Data Collection of primary discharge diagnosis for hospitalisation and 
the Western Australian Deaths Registry have collected data on all hospital facilities and deaths occurring in 
Western Australia since 1980. At the commencement of this study in 1998 participants gave consent to access 
these registries, thus complete ascertainment for all CKD events causing hospitalisation and/or death for the 
14.5 years from 1998 were available for all participants in this study. Deaths Registry data were coded from 
parts 1 and 2 of the death certificate and used the text fields from the death certificate to ascertain the cause(s) 
of deaths when necessary. These CKD events were linked to participants in this study via the Western Australian 
Data Linkage System (WADLS)28. Outcomes were identified using the International Classification of Diseases, 
Injuries and Causes of Death Clinical Modification (ICD-9-CM)29 and the International Statistical Classification 
of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM)30. These codes 
included renal failure (ICD-9-CM codes 585.0–586.0, ICD-10-AM codes N18–19) from the primary discharge 
diagnoses.
Statistical analysis. Baseline characteristics of the study participants were reported as mean (x̅) and stand-
ard deviation (SD) for continuous variables, frequencies (n) and percentages (%) for categorical variables, and 
median (x̃) and interquartile range (IQR) for variables not normally distributed. Baseline serum MDK was not 
normally distributed and was transformed using natural logarithm (ln). Serum MDK levels were used as either 
a continuous variable (ln-transformed, pg/mL), or a dichotomous category below or above the median value. 
Spearman’s correlation was used to assess univariate associations between serum MDK and continuous baseline 
clinical variables. Unadjusted and multivariable-adjusted linear regression analysis was used to assess the associ-
ation between serum MDK with 5-year change in eGFR. The association between serum MDK and rapid decline 
in renal function, defined as an eGFR decline of greater than 15 mL/min/1.73 m2 at 5 years31,32, was assessed 
using unadjusted and multivariable-adjusted logistic regression analysis. The association between serum MDK 
with the occurrence of any CKD-related hospitalisation and death at 14.5 years was assessed using unadjusted 
and multivariable-adjusted Cox regression analysis. No violations of the proportional hazard assumptions were 
detected (p > 0.05). Two models of adjustment were used for all regression analyses: multivariable-adjusted and 
multivariable and baseline eGFR-adjusted. The multivariable-adjusted models included age, calcium treatment 
code, diabetes, and prevalent ASVD. Baseline eGFR was adjusted for separately as eGFR is a strong predictor of 
longitudinal kidney disease outcomes. Results were expressed as either odds or hazard ratio (OR or HR) with 
95% confidence interval (CI) for the logistic and Cox regression models respectively. P values of less than 0.05 in 
two-tailed testing were considered statistically significant. All analyses were performed using IBM SPSS (version 
24; SPSS Inc., Chicago, Ill., USA).
ethics and trial registration. The randomised, controlled trial was commenced and completed before the 
introduction of clinical trial registries, hence the trial was retrospectively registered in the Australian New Zea-
land Clinical Trials Registry ACTRN12615000750583. At baseline written informed consent was obtained from 
all participants for the study and follow-up of electronic health records. The Human Ethics Committee of the 
University of Western Australia approved the study protocol and consent form (Approval Number 05/06/004/
H50). The Human Research Ethics Committee of the Western Australian Department of Health (DOHWA 
HREC) also approved the data linkage study (Approval Number #2009/24).
Results
Baseline characteristics. The median age of this study cohort was 75, with interquartile range (IQR) of 
73 to 77 years. 45.9% and 18.0% of participants were maintained on anti-hypertensive and statin medications, 
respectively, while 6.8% and 13.8% of participants entered the study with prevalent diabetes and ASVD, respec-
tively (Table 1). The mean (± SD) eGFR of the study cohort was 65.1 (± 12.7) mL/min/1.73 m2. 34.1% of partici-
pants had baseline eGFR less than 60 mL/min/1.73 m2.
Baseline serum MDK. Data on serum MDK at baseline was available in 499 women (see Supplemen-
tary Fig. S1 online). Serum MDK levels were not normally distributed (see Supplementary Fig. S2 online). The 
median [IQR] serum MDK level was 437 [328, 580] pg/mL. Baseline characteristics were stratified below or 
above the median serum MDK (Table 1). Neither age nor BMI were different between participants with serum 
MDK above or below the median, nor were correlated with serum MDK (see Supplementary Table S2 online).
A total of 422/499 (84.6%) of participants with data on serum MDK had data on baseline serum creatinine 
and cystatin C to allow calculation of eGFR (see Supplementary Fig. S1 online). Baseline eGFR did not differ 
between participants with serum MDK above or below the median (Table 1). Baseline eGFR, serum creatinine 
and cystatin C were not correlated with serum MDK (Supplementary Table S2 online).
Women with a history of ASVD had serum MDK levels significantly higher than those without (with ASVD 
median [IQR] 503 [385, 666 pg/mL], without ASVD 435 [323, 562 pg/mL], Mann–Whitney U test p = 0.016).
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Serum MDK and 5-year eGFR change/rapid decline in renal function. During follow-up there 
were 297/422 (70.4%) participants from this cohort with data on serum creatinine and cystatin C at 5 years for 
calculation of eGFR (see Supplementary Fig. S1 online). There were no associations between natural logarithm 
(ln)-serum MDK with 5-year eGFR change in unadjusted (Spearman’s rho = − 0.08, p = 0.297), multivariable-
adjusted (Standardised β = − 0.09, 95% CI 3.25–0.40, p = 0.126) or multivariable and baseline eGFR-adjusted 
(Standardised β = − 0.09, 95% CI 3.28–0.28, p = 0.098) analyses. Similarly, below or above-median serum MDK 
was not associated with 5-year eGFR change in unadjusted (Spearman’s rho = − 0.06, p = 0.304), multivariable-
adjusted (Standardised β = − 0.08, 95% CI 3.78–0.56, p = 0.146), or multivariable and baseline eGFR-adjusted 
(Standardised β = − 0.09, 95% CI 3.76–0.48, p = 0.129) analyses. Rapid decline in renal function was identified 
in 33/297 (11.1%) participants at 5 years. There were no associations between ln-serum MDK with 5-year rapid 
decline in renal function in unadjusted (OR 1.20, 95% CI 0.63–2.28, p = 0.573), multivariable-adjusted (OR 
1.23, 95% CI 0.63–2.41, p = 0.538) or multivariable and baseline eGFR-adjusted (OR 1.26, 95% CI 0.64–2.46, 
p = 0.506) analyses. Similarly, below or above-median serum MDK was not associated with 5-year rapid decline 
in renal function in unadjusted (OR 0.96, 95% CI 0.46–1.98, p = 0.902), multivariable-adjusted (OR 0.96, 95% 
CI 0.46–2.01, p = 0.916) or multivariable and baseline eGFR-adjusted (OR 0.97, 95% CI 0.46–2.02, p = 0.927) 
analyses.
Serum MDK and cKD‑related hospitalisations and deaths. CKD-related hospitalisations and 
deaths occurred in 47/499 (9.4%) participants over the 14.5 years of follow-up. The incidence of CKD-related 
hospitalisations and deaths in participants with below-median serum MDK was 18 (7.2%), and in those with 
above-median serum MDK it was 61% higher at 29 (11.6%) (Chi-squared test p = 0.089). In unadjusted Cox 
Proportional Hazard analysis the HR for participants with above-median serum MDK compared to those with 
below-median serum MDK was 1.82 (95% CI 1.01–3.28, p = 0.046). However in multivariable-adjusted, and 
multivariable and baseline eGFR-adjusted analyses the HR were 1.72 (95% CI 0.96–3.11, p = 0.071) and 1.27 
(95% CI 0.66–2.46, p = 0.470), respectively (Table 2 and Fig. 1).
Table 1.  Baseline characteristics expressed based on the total study population or stratified by median 
of serum MDK (n = 499). Results are expressed as mean ± SD, median and [IQR], or number and (%). SD 
standard deviation, IQR interquartile range, MDK Midkine, BMI body mass index, ASVD atherosclerotic 
vascular disease, CKD-EPI eGFR Chronic Kidney Disease Epidemiology Collaboration estimated glomerular 
filtration rate. a Measured in 422 participants using the CKD-EPI creatinine and cystatin C equation.
All participants MDK below median MDK above median p value
Number 499 250 249
MDK, pg/mL 437 [328, 580] 329 [278, 387] 579 [491, 784]
Age, years 75 [73, 77] 75 [73, 77] 75 [73, 78] 0.215
BMI, kg/m2 26.7 [24.0, 29.9] 27.1 [24.6, 30.3] 26.5 [23.3, 29.7] 0.097
Calcium treatment 257 (51.5) 136 (54.4) 121 (48.6) 0.194
Diabetes 34 (6.8) 13 (5.2) 21 (8.4) 0.152
Use of blood pressure lowering medication 229 (45.9) 110 (44.0) 119 (47.8) 0.395
Use of statin 90 (18.0) 43 (17.2) 47 (18.9) 0.626
Prevalent ASVD 69 (13.8) 31 (12.4) 38 (15.3) 0.355
Baseline CKD-EPI eGFR, mL/min/1.73m2a  65.1 ± 12.7 65.4 ± 12.4 64.8 ± 13.0 0.605
Serum creatinine, mg/dL 0.90 ± 0.18 0.89 ± 0.17 0.90 ± 0.19 0.531
Serum cystatin C, mg/dL 1.07 ± 0.22 1.07 ± 0.21 1.08 ± 0.23 0.562
Table 2.  Unadjusted and multivariable-adjusted Cox proportional hazard analysis of serum MDK in 
predicting 14.5-year CKD-related hospitalisations and deaths in elderly women. Multivariable model was 
adjusted for age, calcium treatment code, diabetes and prevalent atherosclerotic vascular disease. MDK 
Midkine, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, HR hazard ratio, CI 
confidence interval.  Bold indicates statistical significance of the p value.
MDK below median (< 437 pg/mL) MDK above median (≥ 437 pg/mL) p value
Number of events (%) 18 (7.2) 29 (11.6)
Unadjusted HR (95% CI) 1.00 (referent) 1.82 (1.01, 3.28) 0.046
Multivariable-adjusted HR (95% CI) 1.00 (referent) 1.72 (0.96, 3.11) 0.071
Multivariable and baseline eGFR-adjusted HR 
(95% CI) 1.00 (referent) 1.27 (0.66, 2.46) 0.470
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Discussion
In this study, the baseline serum MDK levels were consistent to that previously reported in healthy 
 populations18,33, and these levels of serum MDK were not associated with eGFR at baseline, 5-year eGFR decline, 
or 5-year rapid decline in renal function. Although we observed an association between above the median serum 
MDK levels with the risk of 14.5-year CKD-related hospitalisations and deaths in the unadjusted analysis, the 
association was no longer significant after adjusting for age, calcium treatment, diabetes and prevalent ASVD 
with or without baseline eGFR. These results suggest that circulating MDK levels consistent to that of previously 
reported healthy populations is not a useful biomarker in predicting renal function decline over time or CKD-
related clinical events in the healthy, elderly female population.
The study results should be interpreted in context. Previous studies have reported associations between MDK 
and renal dysfunction and clinical outcomes in both AKI and CKD  populations19–21. The discrepancy between 
our results to that of previous findings is likely due to the difference in study population characteristics – we 
examined an elderly yet healthy cohort with minimal comorbidities and disease burden comparable to the general 
 population34, as opposed to other cohorts with established renal disease. These previous findings indicate that 
serum MDK may be a more sensitive biomarker associated with renal function changes when there is marked 
renal injury or dysfunction, and is therefore not as relevant to the early trajectory of renal function decline. We 
have also utilised serum cystatin C in addition to serum creatinine to measure eGFR in our study in contrast 
to previous studies which only utilised serum  creatinine18–21, so the difference in findings may be due to funda-
mental differences in defining renal function.
Our findings may argue that MDK is not an early biomarker in chronic and age-related renal function changes 
and kidney disease outcomes, which is supported by both experimental and clinical evidence on the involve-
ment of MDK in acute inflammation and kidney  injury14,15,20,21. However, given that there are also a few studies 
addressing MDK in chronic inflammation and kidney disease  cases16–18, this reflects the need to consider how 
MDK activity is regulated during the transition from acute to chronic renal inflammation and deterioration.
There were limitations with this study. There was no data available on proteinuria and albuminuria, so we were 
unable to determine if serum MDK was associated with these early indicators of kidney damage. The majority 
of serum MDK levels at baseline were within the normal range consistent with previous  reports18,33. As such, we 
were unable to determine whether abnormal levels of serum MDK were associated with renal function decline 
or CKD-related clinical events. The proportions of the study population that experienced events for 5-year rapid 
decline in renal function and 14.5-year CKD-related hospitalisation and death were small (11.1% and 9.4%, 
respectively), which may have reduced our statistical power. There was loss of samples for data on serum MDK 
Figure 1.  Multivariable-adjusted Cox proportional HR and 95% CI for 14.5-year CKD-related hospitalisations 
and deaths (n = 47) in elderly women stratified by serum MDK below (< 437 pg/mL, dashed red line, referent) or 
above (≥ 437 pg/mL, solid black line) the median. Multivariable model was adjusted for age, calcium treatment 
code, diabetes and prevalent atherosclerotic vascular disease. Multivariable HR 1.72, 95% CI 0.96–3.11, 
p = 0.071. CKD chronic kidney disease, MDK Midkine, HR hazard ratio, CI confidence interval.
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due to changing of the ELISA assay kit lots, which may also have reduced our statistical power. However, this 
is unlikely to have altered the magnitude of the associations as there were no significant differences between 
the characteristics (and therefore potential covariates in association) of the included and excluded cohorts (see 
Supplementary Table S3 online). Since we did not measure serum MDK levels longitudinally, we cannot exclude 
the possibility that MDK is a pathological biomarker in CKD. Finally, our study was limited to generally healthy, 
older predominantly Caucasian women so the findings may not apply to other demographic or disease popula-
tions, such as those with diabetes who are at increased risk of CKD.
The strengths of this study include the use of both serum creatinine and cystatin C for the measurement 
of eGFR, which improved our ability to more accurately define baseline kidney function and CKD outcomes. 
The study had a long follow-up period of 14.5 years, minimal loss to follow-up, and detailed prospective data 
collection using a comprehensive, population-based linkage system. This is also the first study to prospectively 
examine the relationship between MDK, renal function and clinical outcomes of CKD, and therefore provide 
insights to assess the clinical value of MDK as a viable prognostic biomarker.
In conclusion, baseline serum MDK is not associated with long-term renal function decline or CKD-related 
hospitalisations and deaths in healthy, elderly women with normal or mildly impaired renal function. Further 
studies are required to confirm the relationship between MDK and longitudinal renal function and CKD out-
comes in populations with prevalent kidney disease.
Data availability
The datasets generated during and/or analysed in this study can be viewed online at https ://www.lsaw.com.au/ 
and are available from Prof Richard L. Prince at richard.prince@uwa.edu.au on reasonable request.
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